The complex membrane composition of exosomes allows them to deliver their biological messages and thus change the behavior of the recipient cells in two ways: by efficiently entering target cells or by interacting with proteins on the cell’s surface.
Exosomes are, by their very nature, believed to evade the immune system, which allows exosomes to move through the various sensors the body uses to detect and halt the spread of foreign substances.
Codiak presented data at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy demonstrating the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.
Codiak presented data at The Society for Immunotherapy of Cancer (SITC) demonstrating that exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses compared to free STING agonist.
Codiak presented data at The Society for Immunotherapy of Cancer (SITC) supporting that exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12.
Codiak presented data supporting the identification of a novel and selective scaffold protein, PTGFRN, as part of its engEX exosome platform at the Annual Meeting of the International Society for Extracellular Vesicles (ISEV).
Codiak presented data supporting the potential of its engEX™ Platform and its proprietary PTGFRN protein scaffold at the 2019 American Association for Cancer Research (AACR) Annual Meeting
Codiak presented preclinical data in support of its engEx Platform for engineering exosomes at the Keystone Symposium on Cancer Immunotherapy.
Codiak presented results from preclinical studies demonstrating the potential efficacy of exoSTING™, a novel engineered exosome product candidate targeting checkpoint refractory tumors at the Society for Immunotherapy of Cancer (SITC)’s 33rd Annual Meeting.